SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 15.19 |
| Enterprise Value ($M) | 6.60 |
| Book Value ($M) | 8.50 |
| Book Value / Share | 0.90 |
| Price / Book | 1.79 |
| NCAV ($M) | 8.26 |
| NCAV / Share | 0.88 |
| Price / NCAV | 1.84 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -2.86 |
| Return on Assets (ROA) | -2.62 |
| Return on Equity (ROE) | -4.22 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 4.17 |
| Current Ratio | 4.17 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 10.87 |
| Assets | 11.11 |
| Liabilities | 2.61 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Earnings Per Share Basic And Diluted | n/a |
| Earnings Per Share Basic | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Armistice Capital, Llc | 4.99 | -47.62 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 307,913 | 756,054 | 40.73 | |
| 117,878 | 415,839 | 28.35 | |
| 637,495 | 1,424,203 | 44.76 | |
| 190,153 | 556,879 | 34.15 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| GLYC – GlycoMimetics, Inc. | GNLX – Genelux Corporation |
| GNPX – Genprex, Inc. | GRCE – Grace Therapeutics, Inc. |
| GTBP – GT Biopharma, Inc. |
Financial data and stock pages provided by
Fintel.io